View all stories with this category.
Derek Lowe wonders whether we should mourn the decline of classic analytical techniques or embrace technological advances
How long should scientists stay at the bench, asks Derek Lowe. How long is a piece of string?
Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be
A can-do attitude and some lateral thinking can save time and money when it comes to exotic apparatus, says Derek Lowe
Derek Lowe asks (with some trepidation): do drug companies need scientists at the top?
It’s more a research problem, than a commercial one, says Derek Lowe
Derek Lowe investigates the long running tradition of naming reactions after their inventors
How do you reconcile the need for personal safety with unfamiliar compounds, asks Derek Lowe
The pharma industry should be more open with its trial data, says Derek Lowe
Derek Lowe examines an alternative funding model for pharmaceutical research
There might be a better way to interview new starters, suggests Derek Lowe
Derek Lowe asks: Why don’t we use photochemistry more often?
Derek Lowe makes the case against using ‘frequent hitters’ in your assays
Derek Lowe would back a team of risk takers if he had to
Chemists and biologists often view the process of drug discovery very differently
It took Derek Lowe a while to find his motivation
How long is ‘too long’ in the drug discovery game?
Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love
Derek Lowe wonders what the lab lingua franca might be in the years to come
Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
© Royal Society of Chemistry Registered charity number: 207890
Site powered by Webvision Cloud